Iain D. Dukes - 07 Jun 2024 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Reporting relationship: Director
Issuer ticker: IKNA
Reported as of: 07 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2024, 16:15:06 UTC
Prior SEC filing: 03 Apr 2024
Next SEC filing: 13 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Mark Manfredi, as Attorney-in-Fact for Iain D. Dukes

Key filing fact

Iain D. Dukes filed Form 4 for Ikena Oncology, Inc. (IKNA) on 10 Jun 2024.

Key facts

This page summarizes Iain D. Dukes's Form 4 filing for Ikena Oncology, Inc. (IKNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2024, 16:15.

Change

Previous filing in this sequence was filed on 03 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IKNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,520
Change %
Price: $0.000000
Shares after: 17,520
Date: 07 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,520
Exercise price: $1.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest in full upon the earlier of (i) June 7, 2025 or (ii) the date of the next annual meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director.